

## INSTRUCTIONS TO AUTHORS

1. SUBMISSION REQUIREMENTS .....	1
2. ARTICLE TYPES .....	3
3. PREPARING THE SUBMISSION .....	3
4. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS .	6
5. AUTHOR LICENSING .....	9
6. AFTER ACCEPTANCE.....	9
7. COVER IMAGES .....	10
8. APPENDIX.....	10
9. POST PUBLICATION.....	11
10. EDITORIAL OFFICE CONTACT .....	11

### 1. SUBMISSION REQUIREMENTS

Only manuscripts in English are accepted. Contributors should bear in mind the interdisciplinary nature of the readership.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online via the [Journal of Biophotonics online submission site](#).

For article templates, forms and other author resources, please visit the [Author Guidelines](#).

### ARTICLE PREPARATION SUPPORT

[Wiley Editing Services](#) offers expert help with English language editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence. Also, check out our resources for [Preparing Your Article](#) for general guidance about writing and preparing your manuscript. In particular, authors may benefit from referring to Wiley’s best practice tips on [Writing for Search Engine Optimization](#).

### USING THE ONLINE SUBMISSION SYSTEM

- On the journal’s homepage, click the ‘Submit an Article’ option on the right-hand side menu to open the ScholarOne Manuscripts homepage or use the link [JBIO ScholarOne Manuscripts](#).
- Please check first whether you already have an account. If you are unsure whether or not

you have an account, or have forgotten your password, follow the instructions on the log-in screen.

- If you’re a first-time user, use the ‘Create An Account’ link to create an account.
- The submitting author (only) is required to provide an [ORCID ID](#) when submitting their manuscript.
- The system will guide you through the submission process.
- During submission, the author is required to provide information on payment modalities and possible funder arrangements. Be sure to enter all of your funder and grant information during the details & comments step. This helps us ensure you meet all of your funder requirements.

Click here for more details on how to use [ScholarOne](#). For help with submissions, please contact: [jbp@wiley.com](mailto:jbp@wiley.com).

### FREE FORMAT SUBMISSION

*Journal of Biophotonics* offers free format submission for a simplified and streamlined submission process.

Before you submit, you will need:

- Your manuscript: this can be a single file including text, figures, and tables, or separate files—whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers. If your manuscript is difficult to read, the editorial office may send it back to you for revision.
- The title page of the manuscript, including statements relating to our ethics and integrity policies, *if applicable* (see more information in Section Appendix)
  - data availability statement

- funding statement
- conflict of interest disclosure
- ethics approval statement
- patient consent statement
- permission to reproduce material from other sources
- clinical trial registration
- Your co-author details, including affiliation and email address.
- An ORCID ID, freely available at <https://orcid.org>.

If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements as described further down.

## OPEN ACCESS

---

This journal offers authors an open access option to have their article immediately freely available to everyone, including those who do not subscribe.

To cover the cost of publishing with open access, authors pay an article publication charge (APC). The APC for this journal can be found on Wiley's [Pricing](#) page. Some organizations pay APCs for their authors via a [Wiley Open Access Account](#). You can [read more about APCs](#) and whether you may be eligible for waivers or discounts, through your institution, funder, or a [country waiver](#).

## PREPRINT POLICY

---

*Journal of Biophotonics* accepts articles previously published on preprint servers.

The journal will consider for review articles previously available as preprints. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.

Please find the Wiley preprint policy [here](#).

## DATA SHARING AND DATA AVAILABILITY

---

This journal **expects** that data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a Data Availability Statement to describe the availability or the absence of shared data. When data have been shared, authors are required to include in their data availability statement a link to the repository they have used, and to cite the data they have shared. Whenever possible the scripts and other artefacts

used to generate the analyses presented in the paper should also be publicly archived. If sharing data compromises ethical standards or legal requirements then authors are not expected to share it.

The DAS must be included during submission in ScholarOne, in Step Details & Comments - "Data Availability Statement" and preferably also in the Manuscript before the Reference section.

NOTE: If no research data are shared, the DAS will simply state "Research data are not shared."

Review [Wiley's Data Sharing policy](#) where you will be able to see and select the data availability statement that is right for your submission.

## DATA CITATION

---

Please review [Wiley's Data Citation policy](#).

## DATA PROTECTION

---

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at [Data Protection Policy](#).

## FUNDING

---

You should list all funding sources in the Acknowledgments section. You are responsible for the accuracy of their funder designation. If in doubt, please check the [Open Funder Registry](#) for the correct nomenclature.

## AUTHORSHIP

---

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review [editorial standards](#) and scroll down for a description of authorship criteria.

## ORCID

This journal requires ORCID. Please refer to [Wiley's resources on ORCID](#).

## REPRODUCTION OF COPYRIGHT MATERIAL

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit [Wiley's Copyright Terms & Conditions FAQ](#).

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source, and for supplying Wiley with that permission upon submission.

Permissions should be uploaded as "Supporting Information Not for Review". For more information visit [Wiley's Copyright Terms & Conditions FAQ](#).

## 2. ARTICLE TYPES

**Research Articles:** Reports of original research that make a significant contribution to knowledge, with methods, findings and conclusions. A length of about 4,000 words incl. references is recommended.

**Reviews:** Overview of developments in fields or the current lines of thought. Will usually be written at the invitation of the Editors. Unsolicited reviews will be highly welcome but authors wishing to submit a review are requested to consult the Editors prior to commencement. The size of a Review may differ, a length of about 7,000 words incl. references is recommended. A short CV and a photo of each author should be submitted.

**Letters:** Brief observations and research reports that do not warrant a full-length paper. Must be complete, self-contained papers, and not preliminary reports. A length of about 2,300 words plus 1–3 figures and a short reference list is recommended.

## 3. PREPARING THE SUBMISSION

Authors may use the LaTeX or Word templates to format their manuscripts. The templates can be downloaded from the journal homepage [Author Guidelines](#).

The name(s) of any **sponsor(s)** of the research contained in the paper, along with **grant number(s)** should be included in the Acknowledgements section at the end of the main text.

**LaTeX users:** Please submit a **single PDF file generated from the source files**. At this stage, further source files are not required.

Revisions must still be uploaded as a single PDF generated from the revised source files. In addition, please upload your TeX source files including bbl and figure files. For all source files use the File Designation "ZIP of all TeX source files (figs, tables, bib, ...)". Previous versions of uploaded documents must be deleted. If the manuscript is accepted for publication the uploaded files will be used to typeset the article within a totally digital workflow.

## MAIN TEXT FILE

The manuscript should contain the following elements:

- i. A brief informative title (up to 150 characters) containing the major key words. The title should not contain abbreviations (see [Wiley's best practice SEO tips](#));
- ii. The full names of the authors with institutional affiliations where the work was conducted, with a footnote for the author's present address if different from where the work was conducted;
- iii. Abstract (up to 150 words) containing the major keywords;
- iv. Abstract figure;
- v. Keywords: (at least four, up to eight keywords) should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at [www.nlm.nih.gov/mesh](http://www.nlm.nih.gov/mesh);
- vi. Main text;
- vii. Acknowledgments;
- viii. References (numbered in the order of appearance in the text);
- ix. Tables (each table complete with title and footnotes);
- x. Figures and captions;
- xi. Appendices (if relevant).

*Separate high-resolution figure files* (TIFF, EPS or JPG) with a resolution of at least 300 dpi.

Graphical Table of Contents: See further down.

## TITLE

The title should be a short informative title that contains the major key words. The title should not contain abbreviations (see Wiley's [best practice SEO tips](#)).

## ACKNOWLEDGMENTS

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

## CONFLICT OF INTEREST STATEMENT

Authors are asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the 'Conflict of Interest' section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

## EXPERIMENTAL SECTION

The Experimental Part should contain only descriptions of experiments. It must be sufficiently clear to enable a repetition of the work. The source and purity of all relevant starting compounds should be mentioned. Methods used for sample characterization should also be described (apparatus, conditions, etc.). The relevant literature should be cited for known methods and for the description of known compounds; only modifications should be described.

## MATERIALS AND METHODS

If a method or tool is introduced in the study, including software, questionnaires, and scales, the author should state the license this is available under and any requirement for permission for use. If an existing method or tool is used in the research, the authors are responsible for checking the license and obtaining the permission. If permission was required, a statement confirming permission should be included in the Materials and Methods section.

## REFERENCES

All references should be numbered consecutively in order of appearance and should be as complete as possible. The numbers of references should appear in the text in brackets e.g. [1, 21] or [1-4]. Journal titles are abbreviated; abbreviations may be found in the following: [Web of Science](#) or [CalTech Library](#)

Please do not format the references section with the Numbering function of your word-processing program. We recommend the use of a tool such as EndNote (e.g. the [ChemPhysChem endnote style](#), which is similar to the journal style) or Reference Manager ([www.refman.com](http://www.refman.com)) for reference management and formatting.

Submissions are not required to reflect the precise reference formatting of the journal (use of italics, bold etc.), however it is important that all key elements of each reference are included. Please see below for examples of reference content requirements.

→ Please give the **names of all authors** (no "et al.")!

Unpublished results and lectures should only be cited for exceptional reasons.

Reference examples:

### From Journals

Initials. Surnames (of all authors), *Journal Title (abbreviated)*, **Year**, *Vol. No.*, first page, e.g.:

- [1] C. A. Lieber and A. Mahadevan-Jansen, *Opt. Express* **2007**, *15*, 11874.
- [2] U. Neugebauer, P. Rösch, M. Schmitt, J. Popp, C. Julien, A. Rasmussen, C. Budich, and V. Deckert, *ChemPhysChem* **2006**, *7*, 1428.

### Conference proceedings

Please add all available data such as title, date, and place of the conference as well as publisher, place, and year of publication or, alternatively, the corresponding journal information, e.g.:

- [3] V. Piatnitsa, D. Kholodnyak, P. Kapitanova, I. Fischuk, T. Tick, J. Jantti, H. Jantunen, and I. Vendik, in: *Proceedings of the 37th European Microwave Conference*, Munich, Germany, October 2007, p. 636.

### From Books

- [4] J. Berthier and P. Silberzan, *Microfluidics for Biotechnology*, Artech House, Inc, Norwood, 2006, pp. 345.

- [5] T. J. Franz, P. A. Lehman, and E. L. McGuire, in: *Skin Permeation: Fundamentals and Application* (Ed.: J. L. Zatz), Allured, Wheaton, 1993, pp. 93.

## Electronic Material

- [6] Cancer-Pain.org [homepage on the internet]. New York: Association of Cancer Online Resources, Inc.; c2000–01 [Cited 2015 May 11]. Available from: <http://www.cancer-pain.org/>.

## Miscellaneous

- [7] A. Studentname, PhD thesis, University of Newcastle (UK), 1991

## Data citation

- [8] Authors; Year; Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI)

## FOOTNOTES

---

Footnotes can be placed at the foot of each page. They should be referred to in the text with consecutive, superscript Arabic numerals. Keep footnotes brief; they should contain only short comments tangential to the main argument of the paper and should not include references.

## TABLES

---

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶ should be used (in that order) and \*, \*\*, \*\*\* should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

## ARTWORK

---

Figures should preferably be submitted in full color but should also be easily readable on a black/white printout. Color figures are reproduced in color at no cost.

Upload each figure as a separate file in either TIFF, EPS or JPG format. Compound figures e.g. 1a, b, c should be uploaded as one figure. Tints are not acceptable. Lettering must be of a reasonable size that would still be clearly legible upon reduction, and consistent within each figure and set of figures. Where a key to symbols is required, please include this in the artwork itself, not in the figure legend.

All illustrations must be supplied at the correct resolution:

- Black and white and color photos: 300 dpi
- Graphs, drawings, etc: 800 dpi preferred; 600 dpi minimum
- Combinations of photos and drawings (black and white and color): 500 dpi

[Click here](#) for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

## APPENDICES

---

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

## GRAPHICAL TABLE OF CONTENTS

---

The journal's table of contents will be presented in graphical form with a brief abstract.

The table of contents entry must include the article title, the authors' names (with the corresponding author indicated by an asterisk), no more than 80 words or 3 sentences of text summarizing the key findings presented in the paper and a figure that best represents the scope of the paper.

The image supplied should fit within the dimensions of 50mm x 60mm and be fully legible at this size.

Table of contents entries should be submitted on a separate page at the end of the article or uploaded separately as 'Graphical Abstract'.

You must hold the copyright of the figure and it should not be reproduced from an external source without permission.

## SUPPORTING INFORMATION

---

Supporting information is information that is not essential to the article but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

Supplementary material can be cited as part of the original article e.g.

[10] Smith et al., *Transl. Biophotonics* **2019**, *1*, e190024, see online supporting information S1-S5.

You may include captions for supplementary figures, tables or videos at the end of your manuscript.

Please use suitable compression technology to avoid exceedingly large movie files (>10 MB) for the benefit of referees' and readers' bandwidth and storage capacity. Also, please make sure that your movies are saved in a common format (such as MPEG, AVI, QuickTime, GIF) that can be played on at least two different computer platforms (out of Windows/MacOS/ Linux).

Please choose the File Designation "Supporting Information for Review" on the File Upload screen.

[Click here](#) for Wiley's FAQs on supporting information.

## GENERAL STYLE POINTS

The following points provide general advice on formatting and style.

- **Abbreviations:** In general, terms should not be abbreviated unless they are used repeatedly, and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
- **Units of measurement:** Measurements should be given in SI or SI-derived units. Visit the [Bureau International des Poids et Mesures \(BIPM\) website](#) for more information about SI units.
- **Numbers:** numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
- **Trade Names:** Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.
- **Equations:** Equations should be numbered sequentially. Except for small in-line equations, they should appear on separate

lines. Please provide equations in an editable format, like Mathtype. Do not embed equations as graphics. In the text, equations may be referred to by writing "... in Eq. (1)". At the beginning of a sentence, use the full form "Equation (1) shows ...".

## 4. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

### PEER REVIEW

This journal operates under a single-blind [peer review model](#). Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

All contributions will be evaluated according to the standard procedures of peer review, usually by two referees. To facilitate the refereeing process, please **provide the names and email addresses of at least three referees** capable of reviewing your manuscript. Please make sure that the suggested referees are not too closely related to your own publications.

Wiley's policy on the confidentiality of the review process is [available here](#).

This journal participates in [Wiley's Transfer Desk Assistant](#) program.

### GUIDELINES ON PUBLISHING AND RESEARCH ETHICS IN JOURNAL ARTICLES

The journal requires that you include in the manuscript details on IRB approvals, ethical treatment of human and animal research participants, and gathering of informed consent, as appropriate. **You will be expected to declare all conflicts of interest (or none) on submission.** Please review [Wiley's policies](#) surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines.

This journal follows the core practices of the [Committee on Publication Ethics \(COPE\)](#) and handles cases of research and publication misconduct accordingly (<https://publicationethics.org/core-practices>).

This journal uses iThenticate's CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts.

Read [Wiley's Top 10 Publishing Ethics Tips for Authors](#) and [Wiley's Publication Ethics Guidelines](#).

## CONFLICT OF INTEREST

---

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript.

Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, membership of the editorial board of the journal, and consultancy for or receipt of speaker's fees from a company.

Please read the following statements, adding those sections which are relevant at the end of your submitted manuscript under a heading 'Statement of Interests'.

### 1. Authors' declaration of personal interests:

- I. [Name of individual] has served as a speaker, a consultant, an advisory board member for [names of organisations], and has received research funding from [names of organisation].
- II. [Name of individual] is an employee of [name of organisation].
- III. [Name of individual] owns stocks and shares in [name of organisation].
- IV. [Name of individual] owns patent [patent identification and brief description].

The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission, including the following or similar statement: "The authors have stated explicitly that there are no conflicts of interest in connection with this article". It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

### 2. Declaration of funding interests:

- I. This study was funded [in part or in full] by [insert name of funding organisation],

grant number [insert grant or other identification number].

- II. The [writing or preparation] of this paper was funded in part by [insert name of funding organisation].
- III. Initial data analyses were undertaken by [name of individuals if not listed as authors] who are employees of [name company] and received funding from [insert name of funding organisation].

Authors should list all funding sources in the Declarations section. Authors are responsible for the accuracy of their funder designation.

If in doubt, please check the Open Funder Registry for the correct nomenclature: <https://www.crossref.org/services/funder-registry/>.

## PUBLICATIONS BY THE EDITORS OR EDITORIAL BOARD

---

The Editor and Editorial Board members are never involved in editorial decisions about their own work. The Editor, Editorial Board members and other editorial staff (including peer reviewers) will withdraw from discussions about submissions where any circumstances might prevent him/her offering unbiased editorial decisions. In particular, when editorial decisions are required about peer reviewed articles where the Editor or Editorial Board member is an author or is acknowledged as a contributor, the affected Editor or Editorial Board member will exclude themselves and are not involved in the publication decision. When the Editor is presented with papers where their own interests may impair their ability to make an unbiased editorial decision, decisions about the paper are deputised to a suitably qualified individual.

## AUTHORSHIP

---

The journal follows the [ICMJE definition of authorship](#), which indicates that authorship be based on the following 4 criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take

public responsibility for appropriate portions of the content; and

4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #s 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.

**Additional Authorship Options:** Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. 'X and Y should be considered joint first author' or 'X and Y should be considered joint senior author.'

## AUTHOR NAME CHANGE POLICY

---

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author's privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal's Editorial Office with their name change request.

## CORRECTION TO AUTHORSHIP

---

In accordance with Wiley's [Best Practice Guidelines on Research Integrity and Publishing Ethics](#) and the [Committee on Publication Ethics'](#) guidance, the journal will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the [Request for Changes to a Journal Article Author List Form](#) and contact either the journal's editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author's name; the relevant policy for that can be found in [Wiley's Best Practice Guidelines](#) under "Author name changes after publication."]

## ACKNOWLEDGEMENTS

---

Please acknowledge anyone who contributed towards the article who does not meet the criteria for authorship including anyone who provided professional writing services or materials.

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

Group authorship (for manuscripts involving a collaboration group): if you would like the names of the individual members of a collaboration Group to be searchable through their individual PubMed records, please ensure that the title of the collaboration Group is included on the title page and in the submission system and also include collaborating author names as the last paragraph of the "Acknowledgements" section. Please add authors in the format First Name, Middle initial(s) (optional), Last Name. You can add institution or country information for each author if you wish, but this should be consistent across all authors.

## CLINICAL TRIAL REGISTRATION

---

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration

number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

## SPECIES NAMES

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

## GENETIC NOMENCLATURE

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see [varnomen.hgvs.org](http://varnomen.hgvs.org), where examples of acceptable nomenclature are provided.

## SEQUENCE DATA

**Nucleotide sequence data** can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: 'These sequence data have been submitted to the DDBJ/EMBL/ GenBank databases under accession number U12345'. Addresses are as follows:

- DNA Data Bank of Japan (DDBJ): [www.ddbj.nig.ac.jp](http://www.ddbj.nig.ac.jp)
- EMBL Nucleotide Archive: [ebi.ac.uk/ena](http://ebi.ac.uk/ena)
- GenBank: [www.ncbi.nlm.nih.gov/genbank](http://www.ncbi.nlm.nih.gov/genbank)

**Proteins sequence data** should be submitted to either of the following repositories:

- Protein Information Resource (PIR): [pir.georgetown.edu](http://pir.georgetown.edu)
- SWISS-PROT: [expasy.ch/sprot/sprot-top](http://expasy.ch/sprot/sprot-top)

## STRUCTURAL DATA

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). **Please note that the data in**

**databanks must be released, at the latest, upon publication of the article.** We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

- **Organic and organometallic compounds:** Crystallographic data should not be sent as Supporting Information, but should be deposited with the *Cambridge Crystallographic Data Centre* (CCDC) at [ccdc.cam.ac.uk/services/structure%5Fdeposit](http://ccdc.cam.ac.uk/services/structure%5Fdeposit).
- **Inorganic compounds:** *Fachinformationszentrum Karlsruhe* (FIZ; [fiz-karlsruhe.de](http://fiz-karlsruhe.de)).
- **Proteins and nucleic acids:** *Protein Data Bank* ([rcsb.org/pdb](http://rcsb.org/pdb)).
- **NMR spectroscopy data:** *BioMagResBank* ([bmrb.wisc.edu](http://bmrb.wisc.edu)).

## 5. AUTHOR LICENSING

When an accepted article is received by Wiley's production team, the corresponding author will receive an email asking them to login or register with [Wiley Author Services](#). The author will be asked to sign a publication license at this point.

## COPYRIGHT AND LICENSING

Authors may choose to publish under the terms of the journal's standard copyright agreement, or [Open Access](#) under the terms of a Creative Commons License. Note that certain funders mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND [Creative Commons License](#). Please click [here](#) for more information on Wiley's compliance with specific Funder Open Access Policies.

**Open Access fees:** Authors who choose to publish with open access will be charged a fee. A list of Article Publication Charges for Wiley journals is available [here](#).

**Self-Archiving Definitions and Policies:** Note that the journal's standard copyright agreement allows for [self-archiving](#) of different versions of the article under specific conditions.

## 6. AFTER ACCEPTANCE

### FIRST LOOK

After your paper is accepted, your files will be assessed by the editorial office to ensure they are ready for production. You may be contacted if any

updates or final files are required. Otherwise, your paper will be sent to the production team.

## ACCEPTED ARTICLES

The journal offers Wiley's Accepted Articles service for all manuscripts. This service ensures that accepted 'in press' manuscripts are published online shortly after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance and appear in PDF format only. They are given a Digital Object Identifier (DOI), which allows them to be cited and tracked and are indexed by PubMed. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.

## PROOFS

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email.

## EARLY VIEW

The journal offers rapid publication via Wiley's Early View service. [Early View](#) (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

## ARTICLE PROMOTION SUPPORT

[Wiley Editing Services](#) offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

## 7. COVER IMAGES

*Journal of Biophotonics* accepts artwork submissions for Cover Images. This is an optional

service you can use to help increase article exposure and showcase your research.

Your artwork will be featured in the Table of Contents. You will receive a high-resolution PDF file of the cover page for your personal use.

1. Text and line art (graphs, charts, maps, etc.) reproduce best if saved as EPS or PDF. Please remember to embed fonts. This ensures that any text reproduces exactly as you intend.
2. Photographic images are best saved as TIFF or PNG, as this ensures that all data are included in the file. JPEG should be avoided if possible, as information is lost during compression; however, it is acceptable for purely photographic subjects if the image was generated as a JPEG from the outset.
3. Microsoft Office: If you have generated your images in Microsoft Office software (Word, Excel, PowerPoint), or similar software, it is best to send us the files in their native file formats.
4. Please ensure all images are a minimum of 600 dpi.
5. Please also submit a short description of the image or the work it represents.
6. As this is a publishing service for authors we do ask authors to contribute to the publication costs. For more information please contact the publisher at [jbp@wiley.com](mailto:jbp@wiley.com).
7. You must hold the Copyright of the Cover image and it should not be reproduced from an external source without permission.

Further information on cover artwork can be found in our FAQs document: [Guide for Cover Artwork](#).

## 8. APPENDIX

### PUBLICATION CHARGES

**Color figures** are published online free of charge.

**Page Charges:** The journal does not charge for publication.

### RESOURCE IDENTIFICATION INITIATIVE

The journal supports the [Resource Identification Initiative](#), which aims to promote research resource identification, discovery, and reuse. This initiative, led by the [Neuroscience Information](#)

[Framework](#) and the [Oregon Health & Science University Library](#), provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

You will be asked to use RRIDs to cite the resources used in your research where applicable in the text, similar to a regular citation or Genbank Accession number. For antibodies, you should include in the citation the vendor, catalogue number, and RRID both in the text upon first mention in the Methods section. For software tools and databases, please provide the name of the resource followed by the resource website, if available, and the RRID. For model organisms, the RRID alone is sufficient.

Additionally, you must include the RRIDs in the list of keywords associated with the manuscript.

### **To Obtain Research Resource Identifiers (RRIDs):**

Use the [Resource Identification Portal](#), created by the Resource Identification Initiative Working Group.

Search for the research resource (please see the section titled "Search Features and Tips" for more information).

Click on the "Cite This" button to obtain the citation and insert the citation into the manuscript text.

If there is a resource that is not found within the [Resource Identification Portal](#), you are asked to register the resource with the appropriate resource authority. Information on how to do this is provided in the "Resource Citation Guidelines" section of the Portal.

If any difficulties in obtaining identifiers arise, please contact [rii-help@scicrunch.org](mailto:rii-help@scicrunch.org) for assistance.

### **Example Citations:**

- Antibodies: "Wnt3 was localized using a rabbit polyclonal antibody C64F2 against Wnt3 (Cell Signaling Technology, Cat# 2721S, RRID: AB\_2215411)"
- Model Organisms: "Experiments were conducted in *C. elegans* strain SP304 (RRID:CGC\_SP304)"

- Cell lines: "Experiments were conducted in PC12 CLS cells (CLS Cat# 500311/p701\_PC-12, RRID:CVCL\_0481)"
- Tools, Software, and Databases: "Image analysis was conducted with CellProfiler Image Analysis Software, V2.0 (<http://www.cellprofiler.org>, RRID:nif-0000-00280)"

## 9. POST PUBLICATION

When the article is published online:

- The author receives an email alert (if requested).
- The link to the published article can be shared through social media.
- The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
- The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

### **Make your article discoverable online!**

Consult our [Search Engine Optimization \(SEO\) Tips](#) in order to maximize online discoverability for your published research. Read more about SEO and how to promote your work here: [Promotional Toolkit](#).

**Video summaries:** A video summary can be a quick way to make the message of your research accessible to a much larger audience. Wiley and its partner Research Square offer a service of professionally produced video summaries, available to authors of articles accepted in this journal. You can learn more about it at [Video Summaries](#). If you have any questions, please direct them to [videoabstracts@wiley.com](mailto:videoabstracts@wiley.com).

## 10. EDITORIAL OFFICE CONTACT

### **Editorial Office**

Phone: +49-3641-948367

Fax: +49-3641-948302

E-mail: [jbp@uni-jena.de](mailto:jbp@uni-jena.de)

**Publisher contact:** [jbp@wiley.com](mailto:jbp@wiley.com)

Author Guidelines and further author resources can be found here: [www.biophotonics-journal.org](http://www.biophotonics-journal.org) → [Contribute](#)